Tsevat Danielle G, Miller Vanessa, Hodges Mia, Mizelle Celia, Kessel Julia, Sauer Gretchen, Arora Kavita S, Allison James H, Allison Bianca A
Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill, Chapel Hill, NC; Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Am J Obstet Gynecol. 2025 Mar 22. doi: 10.1016/j.ajog.2025.03.021.
Although offering pain management with intrauterine device placement is recommended, but no standardized protocol exists. Patients may experience disparities pain regimens offered with placement based on where they seek care.
This study aimed to describe the pain medication regimens that clinicians use for intrauterine device placement and the patient and clinician factors and clinic settings associated with receiving medication before and during placement.
We performed a retrospective study of nulliparous individuals aged 15 to 50 years who had an intrauterine device placed from 2019 to 2021 (N=1153) across a large statewide health system in the Southeast. From the electronic health record, we abstracted exposure variables (ie, patient, clinician, and clinic characteristics) and outcomes (ie, medication regimens used before and during intrauterine device placement). We used bivariate analysis and multivariable logistic regression to examine associations between exposure variables and outcomes.
Less than half of the patients (41.7%) received medications before or during intrauterine device placement. Medication regimens used before and during intrauterine device placement varied by clinician specialty, clinician type, and clinic location. After multivariable regression, patients were more likely to receive preinsertion medications if they had a lower body mass index, received the Skyla intrauterine device, were treated by advanced practice providers or clinicians with a specialty in pediatrics or internal medicine, or were seen in >1 clinic visit for their intrauterine device placement (all P<.01). Patients were more likely to receive pain medications during intrauterine device placement if they were younger, treated by internal medicine clinicians, or had their intrauterine device placed on the same day they requested it, and they were less likely to receive medications during placement if seen by advanced practice providers or in a rural setting (all P<.01). There were no differences by patient race or insurance type.
We found that pain management with intrauterine device placement is associated with clinician specialty, clinician type, and practice setting, with few significant patient factors. Although no particular pain regimen is universally recommended, several options have been shown to be potentially beneficial for nulliparous patients. Therefore, improving clinician knowledge about effective pain regimens and expanding resources across all clinic settings may improve nulliparous patients' experiences and shared decision-making regarding medication use before and during intrauterine device placement.
尽管建议在放置宫内节育器时进行疼痛管理,但目前尚无标准化方案。患者根据就诊地点接受的放置疼痛治疗方案可能存在差异。
本研究旨在描述临床医生在放置宫内节育器时使用的疼痛药物治疗方案,以及与放置前和放置期间接受药物治疗相关的患者、临床医生因素和诊所环境。
我们对2019年至2021年在东南部一个大型全州卫生系统中放置宫内节育器的15至50岁未生育个体进行了一项回顾性研究(N = 1153)。从电子健康记录中,我们提取了暴露变量(即患者、临床医生和诊所特征)和结局(即放置宫内节育器前和放置期间使用的药物治疗方案)。我们使用双变量分析和多变量逻辑回归来检验暴露变量与结局之间的关联。
不到一半的患者(41.7%)在放置宫内节育器之前或期间接受了药物治疗。放置宫内节育器之前和期间使用的药物治疗方案因临床医生专业、临床医生类型和诊所位置而异。多变量回归后,如果患者体重指数较低、使用Skyla宫内节育器、由高级执业提供者或儿科或内科专业的临床医生治疗,或者因放置宫内节育器就诊超过1次,则更有可能接受放置前药物治疗(所有P <.01)。如果患者年龄较小、由内科临床医生治疗,或者在请求放置宫内节育器的当天进行放置,则在放置宫内节育器期间更有可能接受疼痛药物治疗;如果由高级执业提供者治疗或在农村环境中就诊,则在放置期间接受药物治疗的可能性较小(所有P <.01)。患者种族或保险类型无差异。
我们发现,放置宫内节育器时的疼痛管理与临床医生专业、临床医生类型和执业环境有关,患者因素影响较小。虽然没有普遍推荐的特定疼痛治疗方案,但已证明几种方案可能对未生育患者有益。因此,提高临床医生对有效疼痛治疗方案的认识,并在所有诊所环境中扩大资源,可能会改善未生育患者在放置宫内节育器之前和期间使用药物的体验以及共同决策。